Ji-Yuan Zhang

Ji-Yuan Zhang

Auto-generated profile, based on publicly available information

Ji-Yuan Zhang

Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JZJi-Yuan Zhang
Ji-Yuan Zhang
XWXiang-Ming Wang
Xiang-Ming Wang
XXXudong Xing
Xudong Xing
ZXZhe Xu
Zhe Xu
CZChao Zhang
Chao Zhang
FWFusheng Wang
Fusheng Wang

1 August 2020 in Cell Metabolism
Verified
Journal Article
Closed access
JSJin-Wen Song
Jin-Wen Song
SLSin Man Lam
Sin Man Lam
XFXing Fan
Xing Fan
WCWen-Jing Cao
Wen-Jing Cao
SWSi-Yu Wang
Si-Yu Wang
GSGuanghou Shui
Guanghou Shui

8 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJin-Wen Song
Jin-Wen Song
CZChao Zhang
Chao Zhang
XFXing Fan
Xing Fan
FMFan-Ping Meng
Fan-Ping Meng
ZXZhe Xu
Zhe Xu
JZJi-Yuan Zhang
Ji-Yuan Zhang
COVID-19 is associated with 5.1% mortality. Although the virological, epidemiological, clinical, and management outcome features of COVID-19 patients have been defined rapidly, the inflammatory and immune profiles require definition as they influence pathogenesis and clinical expression of COVID-19. Here we show lymphopenia, selective loss of CD4+ T cells, CD8+ T cells and NK cells, excessive T-cell activation and high expression of T-cell inhibitory molecules are more prominent in severe cases than in those with mild disease. CD8+ T cells in patients with severe disease express high levels of cytotoxic molecules. Histochemical studies of lung tissue from one fatality show sub-anatomical distributions of SARS-CoV-2 RNA and massive infiltration of T cells and macrophages. Thus, aberrant activation and dysregulation of CD8+ T cells occur in patients with severe COVID-19 disease, an effect that might be for pathogenesis of SARS-CoV-2 infection and indicate that immune-based targets for therapeutic interventions constitute a promising treatment for severe COVID-19 patients.

8 June 2020 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
CAChiara Agrati
Chiara Agrati
ASAlessandra Sacchi
Alessandra Sacchi
VBVeronica Bordoni
Veronica Bordoni
ECEleonora Cimini
Eleonora Cimini
SNStefania Notari
Stefania Notari
GIGiuseppe Ippolito
Giuseppe Ippolito
SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease. The pathogenesis of severe cases remains unknown. We performed an in-depth prospective analysis of immune and inflammation markers in two patients with severe COVID-19 disease from presentation to convalescence. Peripheral blood from 18 SARS-CoV-2-infected patients, 9 with severe and 9 with mild COVID-19 disease, was obtained at admission and analyzed for T-cell activation profile, myeloid-derived suppressor cells (MDSCs) and cytokine profiles. MDSC functionality was tested in vitro. In four severe and in four mild patients, a longitudinal analysis was performed daily from the day of admission to the early convalescent phase. Early after admission severe patients showed neutrophilia, lymphopenia, increase in effector T cells, a persisting higher expression of CD95 on T cells, higher serum concentration of IL-6 and TGF-β, and a cytotoxic profile of NK and T cells compared with mild patients, suggesting a highly engaged immune response. Massive expansion of MDSCs was observed, up to 90% of total circulating mononuclear cells in patients with severe disease, and up to 25% in the patients with mild disease; the frequency decreasing with recovery. MDSCs suppressed T-cell functions, dampening excessive immune response. MDSCs decline at convalescent phase was associated to a reduction in TGF-β and to an increase of inflammatory cytokines in plasma samples. Substantial expansion of suppressor cells is seen in patients with severe COVID-19. Further studies are required to define their roles in reducing the excessive activation/inflammation, protection, influencing disease progression, potential to serve as biomarkers of disease severity, and new targets for immune and host-directed therapeutic approaches.

15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CZChao Zhang
Chao Zhang
JSJin-Wen Song
Jin-Wen Song
HHHui-Huang Huang
Hui-Huang Huang
XFXing Fan
Xing Fan
LHLei Huang
Lei Huang
FWFusheng Wang
Fusheng Wang
Chronic HIV-1 infection is generally characterized by progressive CD4+ T cell depletion due to direct and bystander death that is closely associated with persistent HIV-1 replication and an inflammatory environment in vivo. The mechanisms underlying the loss of CD4+ T cells in patients with chronic HIV-1 infection are incompletely understood. In this study, we simultaneously monitored caspase-1 and caspase-3 activation in circulating CD4+ T cells, which revealed that pyroptotic and apoptotic CD4+ T cells are distinct cell populations with different phenotypic characteristics. Levels of pyroptosis and apoptosis in CD4+ T cells were significantly elevated during chronic HIV-1 infection, and decreased following effective antiretroviral therapy. Notably, the occurrence of pyroptosis was further confirmed by elevated gasdermin D activation in lymph nodes of HIV-1–infected individuals. Mechanistically, caspase-1 activation closely correlated with the inflammatory marker expression and was shown to occur through NLRP3 inflammasome activation driven by virus-dependent and/or -independent ROS production, while caspase-3 activation in CD4+ T cells was more closely related to T cell activation status. Hence, our findings show that NLRP3-dependent pyroptosis plays an essential role in CD4+ T cell loss in HIV-1–infected patients and implicate pyroptosis signaling as a target for anti–HIV-1 treatment.

30 November 2021 in Hepatology International
Verified
Journal Article
Open access
PDF file
FMFanping Meng
Fanping Meng
JZJinfang Zhao
Jinfang Zhao
ATAnthony Tanoto Tan
Anthony Tanoto Tan
WHWei Hu
Wei Hu
SWSi-Yu Wang
Si-Yu Wang
FWFusheng Wang
Fusheng Wang
Background & aims: Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation was reported to be safe and had potential therapeutic efficacy. We aim to investigate the safety of HBV-TCR-T-cell immunotherapy in advanced HBV-HCC patients who had not met the criteria for liver transplantation. Methods: We enrolled eight patients with advanced HBV-HCC and adoptively transferred short-lived autologous T cells expressing HBV-specific TCR to perform an open-label, phase 1 dose-escalation study (NCT03899415). The primary endpoint was to evaluate the safety of HBV-TCR-T-cell therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) during the dose-escalation process. The secondary endpoint was to assess the efficacy of HBV-TCR-T-cell therapy by evaluating the anti-tumor responses using RECIST criteria (version 1.1) and the overall survival. Results: Adverse events were observed in two participants among the 8 patients enrolled. Only one patient experienced a Grade 3 liver-related adverse event after receiving a dose of 1 × 105 HBV-TCR-T cells/kg, then normalized without interventions with immunosuppressive agents. Among the patients, one achieved a partial response lasting for 27.7 months. Importantly, most of the patients exhibited a reduction or stabilization of circulating HBsAg and HBV DNA levels after HBV-TCR-T-cell infusion, indicating the on-target effects. Conclusions: The adoptive transfer of HBV-TCR-T cells into advanced HBV-HCC patients were generally safe and well-tolerated. Observations of clinical efficacy support the continued development and eventual application of this treatment strategy in patients with advanced HBV-related HCC. Clinical trials registration: This study was registered at ClinicalTrials.gov (NCT03899415).